Craft

ST Pharm

Stock Price

₩94.7 K

2024-10-29

Market Capitalization

₩1.9 T

2024-10-29

Revenue

₩331.7 B

FY, 2025

ST Pharm Summary

Company Summary

Overview
ST Pharm (formerly known as Samchully Pharmaceutical) is a company that manufactures nucleoside-related pharmaceuticals and intermediates. It provides contract development and manufacturing services and focuses on small molecule, generic, and oligonucleotide active pharmaceutical ingredients (APIs) as well as on the drug discovery and fine chemical areas.
Type
Public
Status
Active
Founded
1983
HQ
Siheung-si, KR | view all locations
Website
https://www.stpharm.co.kr/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Kyungjin Peter Kim
  • Joosung James Yang

    Joosung James Yang, Senior Vice President, Head of Biotech R&D Division

  • Sunki Chang

    Sunki Chang, Senior Vice President, Head of Manufacturing Division

    • Kyungyeon Scott Kim

      Kyungyeon Scott Kim, Senior Vice President, Head of Corporate Quality Division

      LocationsView all

      1 location detected

      • Siheung-si, Gyeonggi-do HQ

        Korea (Republic of)

        231 Hyeopjeong-ro

      ST Pharm Financials

      Summary Financials

      Revenue (FY, 2025)
      ₩331.7B
      Gross profit (FY, 2025)
      ₩162.8B
      Net income (FY, 2025)
      ₩54.6B
      Cash (FY, 2025)
      ₩30.5B
      EBIT (FY, 2025)
      ₩54.6B
      Enterprise value
      $1.9T

      Footer menu